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This Atlas of Teratomas derived from xenografted human pluripotent embryonic stem cells 
is dedicated to Leroy C. Stevens (1922 -2015), a pioneer of mouse teratoma research 
and the forefather of all of us working in this field.
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Preface 
Pluripotent human stem cells: standing on the shoulders of  giants
The advent of  human pluripotent stem cells, with the first derivation of  human embryonic stem cells in 1998 (Thomson 
et al., 1998), and of  human induced pluripotent stem cells in 2007 (Takahashi et al., 2007; Yu et al., 2007), has ushered in 
an era of  considerable excitement about the prospects of  using these cells to develop new opportunities for healthcare, 
from their potential for regenerative medicine to their use as tools for studying the cellular basis of  many diseases and 
the discovery of  new drugs. But as with the flowering of  many new areas in science, the biology of  human pluripotent 
stem cells has its roots in a long history of, sometimes, less fêted research (Solter, 2006). In a period when research 
funding is frequently driven by a desire to meet specific clinical or economic goals, it is salutary to remember that the 
opportunities offered by human pluripotent stem cells have their origins in curiosity-driven research without any of  
those goals in mind.
In this case, that research focused on the relatively rare gonadal cancers known as teratomas, tumors that have fascinated 
people since antiquity because of  their sometimes grotesque manifestations with haphazard collections of  tissues and 
sometimes recognizable body parts (Damjanov and Solter, 1974). Although well-known to clinical pathologists, it was 
the pioneering work of  Leroy C. Stevens, who first discovered that teratomas occur at a significant rate in the 129 strain 
of  the laboratory mouse and could be produced experimentally (Stevens and Little, 1954; Stevens, 1967), that laid the 
foundations for our understanding of  the biology of  these tumors and the central role of  the embryonal carcinoma 
cell, one of  the archetypal tumor stem cells.
Teratocarcinomas are teratomas that also contain embryonal carcinoma cells, undifferentiated cells that had been sug-
gested to give rise to the array of  somatic cells characterizing these tumors (Friedman and Moore, 1946). In a ground-
breaking study, Kleinsmith and Pierce (1964) showed that single cells from a teratocarcinoma of  the laboratory mouse 
could generate a new teratocarcinoma after transplantation to a new host. These results, in parallel with studies in the 
hematopoietic system (Till and McCullough, 1961) and other adult tissues, such as the skin and intestine (Potten and 
Lajtha, 1982) led to the development of  the concepts of  stem cells with their dual properties of  indefinite proliferation 
(self-renewal) and a capacity to initiate differentiation into terminal, functional cell types. From these observations, 
Pierce developed the notion that tumors in general represent caricatures of  their tissue of  origin, and arise from defects 
in differentiation, as much as from dysregulated proliferation (Pierce 1974).
Stevens, and also Nikola Skreb and his colleagues, confirmed suspicions of  a close link between teratomas and embryos 
by showing that these tumors could also be derived from embryos transplanted to ectopic sites (Stevens, 1970; Solter et 
al., 1970). Meanwhile, lines of  embryonal carcinoma cells were established in vitro (Finch and Ephrussi, 1967). These 
cultured cells remained pluripotent, being able to differentiate, not only into teratomas in vivo, but also when grown 
in culture (Jakob et al., 1973; Martin and Evans, 1974). The dramatic finding of  Brinster (1974) that these cultured 
tumor stem cells were also able to contribute to normal embryonic development after transfer to a blastocyst to yield 
a chimeric mouse, confirmed by Papaioannou et al. (1975) and Mintz and Illmensee (1975), provided a final confirma-
tion that embryonal carcinoma cells were caricatures of  the pluripotent inner cell mass cells of  the early embryo. In 
a final turn of  the wheel, Evans and Kaufman (1981) and, separately, Martin (1981), showed that murine pluripotent 
cells could be derived directly from the inner cell mass cultured in vitro under conditions that had been developed for 
the maintenance of  embryonal carcinoma cells. These embryonic stem cells differed from the embryonal carcinomas 
cells by being more efficient at forming embryo chimeras, which included germ line chimerism, probably because they 
had not adapted genetically to tumor growth. But they too would form teratomas when grown in adult mice. 
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As with murine embryonic stem cells, the development of  human embryonic stem cells was preceded by studies of  hu-
man embryonal carcinoma cells derived from teratocarcinomas, obtained during therapy, beginning with xenografted 
lines established by Pierce in the 1950’s (Pierce et al., 1957; Fogh and Trempe, 1975; Hogan et al., 1976; Andrews et al., 
1980). Several of  these lines were able to differentiate extensively both in vitro and in vivo, in xenograft tumors grown in 
immunosuppressed mice (Andrews et al., 1984; Andrews, 1984; Pera et al., 1989; Damjanov et al., 1993). Nevertheless, 
human embryonic stem cells, when derived directly from human embryos, proved to have a much wider capacity to 
differentiate, and to be karyotypically diploid, opening up the prospects for their use in regenerative medicine (Thomson 
et al., 1998; Reubinoff et al., 2000).
With thoughts of  developing applications, the need for tools for characterizing these cells became paramount. To this 
end, the International Stem Cell Initiative (ISCI) was founded in 2004 as a consortium of  researchers from around 
the world, funded by the International Stem Cell Forum (http://www.stem-cell-forum.net/), focused on developing 
standards for human pluripotent stem cell biology. Among studies carried out by the ISCI were the characterization 
of  markers of  the undifferentiated cells (ISCI, 2007), a comparison of  culture media (ISCI, 2010) and a study of  the 
common genetic variants that occur in human pluripotent stem cells on prolonged culture in vitro (ISCI, 2011). Never-
theless, central to work with both embryonic stem cells and, perhaps, even more so with induced pluripotent stem cells, 
is the ability to confirm their pluripotency. For human cells, the gold standard has been their ability to form teratomas 
containing derivatives of  all three embryonic germ layers, ectoderm, mesoderm and endoderm, following growth in 
immunocompromised mice. Although other, in vitro, tests of  differentiation capacity are also used, teratomas provide 
not only insights into differentiation capacity itself, but also the ability of  the cells to form organoid structures that can 
aid the recognition of  particular cell lineages. Importantly, teratomas also offer insights into the potential malignancy 
of  the undifferentiated cells and some of  their derivatives, building on a long experience of  the clinical pathology of  
these tumors. In this Atlas, produced on behalf  of  the ISCI, we have harked back to the clinical pathology of  human 
teratomas to provide a guide for those reviewing the histology of  xenograft tumors produced by human pluripotent 
stem cells.
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